The eVOLVE-Lung02 trial is a global, randomized, open-label Phase?III study comparing volrustomig (MEDI5752) plus platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy in adults with first-line metastatic non-small cell lung cancer (NSCLC) lacking EGFR, ALK or ROS1 driver alterations. The primary objective is to evaluate efficacy (e.g., progression-free survival) and safety of the novel synergy of volrustomig and chemotherapy. Eligible participants are adults with histologically or cytologically confirmed stage?IV NSCLC, no sensitizing EGFR mutation or ALK/ROS1 rearrangement, and who are treatment-naïve for systemic therapy. Molecular driver status is confirmed as negative at screening. Participants are randomised 1:1 between the two treatment arms. Key secondary endpoints include objective response rate (ORR), duration of response (DOR), overall survival (OS) and safety/tolerability profiles.
This study evaluates whether a novel immunotherapy combination (volrustomig plus chemotherapy) can improve outcomes compared to the standard treatment regimen (pembrolizumab plus chemotherapy) in adults with advanced, metastatic non-small cell lung cancer (NSCLC) who are receiving first-line systemic therapy and do not have EGFR, ALK or ROS1 driver mutations. The aim is to assess safety and efficacy of the new treatment. Key outcomes include monitoring side effects and patient survival.C)
